1204221-17-9

Upstream product

• 32469-28-6 (3R,4S,5R,6R)-3,4,5-tris((trimethylsilyl)oxy)-6-(((trimethylsilyl)oxy)methyl)tetrahydro-2H-pyran-2-one 
• 1204219-55-5 (3R,4S,5S,6R)-2-(4-chloro-3-((4-(methoxy-d3)phenyl)methyl-d2)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol 
• 1204219-53-3 4-bromo-1-chloro-2-((4-(methoxy-d3)phenyl)methyl-d2)benzene 
• 1204219-82-8 4-bromo-1-chloro-2-(4-(methoxy-d3)benzyl)benzene 
• 1204219-31-7 4-bromo-1-chloro-2-((4-ethoxyphenyl)methyl-d2)benzene 
• 864070-18-8 4-(5-bromo-2-chlorobenzyl)phenol 
• 461432-23-5 4-bromo-1-chloro-2-[(4-ethoxyphenyl)methyl]benzene 
• 461432-22-4 (5-bromo-2-chlorophenyl)(4-ethyloxyphenyl)methanone 
• 1548876-94-3 4-bromo-1-chloro-2-((4-methoxyphenyl)methyl-d2)benzene 
• 333361-49-2 (5-bromo-2-chlorophenyl)(4-methoxyphenyl)methanone 
• 21900-52-7 5-bromo-2-chloro-benzoyl chloride 
• 21739-92-4 5-bromo-2-chlorobenzoic acid 
• 1548877-02-6 (4-((5-bromo-2-chlorophenyl)methyl-d2)phenoxy)(tertbutyl)dimethylsilane 
• 1204219-40-8 4-((5-bromo-2-chlorophenyl)methyl-d2)phenol 

Downstream Products

• 1204221-55-5 (2S,3R,4R,5S,6R)-2-(4-chloro-3-((4-(2-(2,2-difluoroethoxy)ethoxy)phenyl)methyl-d2)phenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol 
• 1204219-36-2 (2S,3R,4R,5S,6R)-2-(4-chloro-3-((4-ethoxyphenyl)methyl-d2)-phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 1204219-51-1 (2S,3R,4R,5S,6R)-2-(4-chloro-3-((4-(ethoxy-d5)phenyl)-methyl-d2)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 1204219-57-7 (2S,3R,4R,5S,6R)-2-(4-chloro-3-((4-(methoxy-d3)phenyl)-methyl-d2)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 

Relevant academic research and scientific papers

Design, synthesis, and biological evaluation of deuterated C-aryl glycoside as a potent and long-acting renal sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes

SGLT2 inhibitors deuterated at sites susceptible to oxidative metabolism were found to have a slightly longer tmax and half-life (t 1/2), dose-dependent increase in urinary glucose excretion (UGE) in rats, and slightly superior effects on UGE in dogs while retaining similar in vitro inhibitory activities against hSGLT2. In particular, deuterated compound 41 has the potential to be a robust long-acting antidiabetic agent.

DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE

Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions that are affected by SGLT inhibition.